bepecin (BPC-157) / Pliva - LARVOL DELTA

Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. (PubMed, Mo Med) - "These unregulated substances-including the veterinary anabolic steroid trenbolone, investigational triple-agonists like retatrutide, and unapproved peptides such as BPC-157, TB-500, and melanotan-II-lack established human safety profiles. This review differentiates evidence-based therapeutics from unproven, high-risk compounds and outlines the molecular mechanisms of toxicity associated with popular "looksmaxxing" injectables. Clinicians must recognize these trends, and counsel patients on potential long-term health hazards of these potent agents."

Journal • Review • Cardiovascular • Oncology

Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. (PubMed, Int J Pharm Compd) - "These products are promoted for a wide range of uses, including tissue repair, inflammation, metabolic health, and healthy aging. This article examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders."

Journal • Review • Inflammation

Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: University of Arkansas

New P1 trial

Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis. (PubMed, Appl Biochem Biotechnol) - "ELISA showed significant downregulation of proinflammatory cytokines TNF-α, IL-1β, and IL-6 in gastric tissue. These results suggest a biotechnological production strategy for BPC 157 and applications for gastric ulcer treatment."

Journal • Inflammation • Mucositis • Peptic Ulcer • IL1B • IL6 • TNFA

The Hidden Cost of Enhancement: Liver Injury Associated With Peptide BPC-157 (ACG 2026) - "Figure: Figure 1: MRCP results from hospital day 1 (a) and repeat MRCP (b) from hospital day 4. Figure: Table 1: Serial hepatic function monitoring demonstrating laboratory trends from Day 1 of admission, peaking on Day 5, and demonstrating improvement by the time of discharge."

Autoimmune Hepatitis • Dyslipidemia • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Obstructive Sleep Apnea • Pancreatitis • Respiratory Diseases • Sleep Disorder

Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. (PubMed, Curr Pain Headache Rep) - "This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-related peptides, and cibinetide (ARA-290). By synthesizing the available literature, this review aims to provide an evidence-based framework for understanding the potential role of these therapeutic peptides in chronic pain management. However, because most of these therapies remain unapproved by the U.S. Food and Drug Administration (FDA) and clinical evidence in humans is limited, their use should be guided by careful clinical judgment and ongoing evaluation of emerging evidence."

Journal • Review • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • TMSB4X

The Rise of Peptide Therapies and Anesthetic Risk: A Case Report Emphasizing Preoperative Medication Disclosure (ASA 2026) - "Peptide therapies including GLP-1 agonists (aspiration risk from delayed gastric emptying), BPC-157 (unapproved, potential local anesthetic interactions), melanotan 1/2 (cardiovascular effects), and PT-141/bremelanotide (cardiovascular effects) are increasingly used but rarely disclosed by patients. These substances, often obtained through unregulated sources, carry significant anesthetic risks including aspiration, hemodynamic instability, and drug interactions. Systematic preoperative screening with direct questioning about weight loss medications, supplements, and wellness peptides is essential for patient safety."

Case report • Clinical • Cardiovascular • Gastroenterology

Peptide Supplements and Their Therapeutic Applications in Sports Medicine. (PubMed, Am J Sports Med) - "Despite promising findings in animal studies, the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials. Documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance. Because of the lack of robust efficacy and safety data, peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • TMSB4X

Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel. (PubMed, 3 Biotech) - "The fabricated hydrogel also showed a hemolysis rate of less than 5%, indicating acceptable hemocompatibility. Collectively, these findings indicate that CH/BPC hydrogel possesses desirable physicochemical and antibacterial characteristics, highlighting their potential as multifunctional hydrogel for future biomedical applications."

Journal • Hematological Disorders

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. (PubMed, Jt Dis Relat Surg) - "In this exploratory rat model study, both BPC-157 and TB-500 were associated with improved histopathological parameters and extracellular matrix organization during early Achilles tendon repair, with TB-500 additionally demonstrating a significant biomechanical advantage at four weeks. The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways; however, this hypothesis requires further experimental confirmation. These preliminary findings indicate that both peptides warrant further investigation as candidate adjuncts to tendon repair, pending dose-optimization and longer-term studies."

Journal • Preclinical • TMSB4X

Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats. (PubMed, J Physiol Pharmacol) - "Thereby, in general, a triple NO-agent approach can reveal all essential gentamicin points of the NO-system (attenuation (L-NAME)/worsening (L-arginine)), revealing the full spectrum of the NO-system functions. Combined with the BPC 157 application, the triple NO-agent approach shows BPC 157's full efficacy in maintaining and/or reestablishing NO-system effects and functions, and kidney integrity in the gentamicin-rats."

Journal • Preclinical

Effect of BPC-157 Injections on Early Outcomes After Rotator Cuff Repair (AOSSM 2026) - No abstract available

Performance & promises: a social media review of alleged indications, risks and usage of "peptides" in musculoskeletal health (AOSSM 2026) - "BPC-157 was the most frequently mentioned peptide, often recommended in conjunction with TB-500. Promoted benefits included: healing of soft tissue, tendon, and bone injuries (51.2%), improved muscle and joint recovery (39.5%), anti-inflammatory effects (32.6%), enhanced cognition and mood (20.9%), improved metabolism and longevity (14.0%).Ipamorelin, CJC-1295, and IGF1-LR3 were the other most popular peptides... Peptides are being widely advertised and sold through social media, often with exaggerated claims and minimal regulatory oversight. Most posts extrapolate from preclinical or anecdotal data, marketing peptides as panaceas for health, performance, and aesthetics, as evidenced by the poor DISCERN scores. The absence of clinical trials and safety data highlight concerns for responsible use."

Review • Musculoskeletal Diseases • IGF1

Concurrent Session IV- AOSSM STOP Sports Injury- Hype, Hope, or Harm? Peptides, BPC-157 and the New Performance Wild West (AOSSM 2026) - No abstract available

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. (PubMed, Analyst) - "The method was successfully applied to samples containing sub-ng levels of ibutamoren, confirming that the analytical procedure presented in this study is fit for purpose within the doping-control framework. At 4 and 22 °C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after one week in serum and plasma, whereas BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation only in serum. In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs."

Journal

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. (PubMed, Int J Mol Sci) - "Overall, this work demonstrates that BPC-157 and its hybrid analogs act as reversible competitive AChE inhibitors, with enhanced activity observed for structurally modified derivatives. The results highlight the potential of peptide-based hybrid molecules as multifunctional candidates in the development of novel therapeutics targeting cholinergic dysfunction."

Journal • Alzheimer's Disease • CNS Disorders • Pain

Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. (PubMed, Integr Med (Encinitas)) - "This review examines the mechanistic rationale for peptide interventions relevant to thyroid biology and summarizes the current state of evidence for selected peptides, including thymosin alpha-1, thymosin beta-4, BPC-157, and growth hormone secretagogues. Substantial evidence gaps persist, and well-designed thyroid-focused clinical trials are needed to clarify safety, efficacy, and appropriate clinical roles. Peptide therapeutics, therefore, represent a developing research domain whose relevance to thyroid care remains to be established through rigorous investigation."

Journal • Review • Endocrine Disorders • Immune Modulation • Immunology • Solid Tumor • TMSB4X

When The Miles Outrun The Metabolism (ACSM 2026) - "He denied supplements, steroid, or opioid use other than BPC 157...Endocrinology started the patient on Clomiphene citrate 25 mg. Labs: AM testosterone 48, LH 1.8, FSH 7.1, TSH 5.19, cortisol 23.7, vitamin D 52, prolactin 13, Hgb 13.1, MCV 94.4, CMP normal, repeat XR of knee was normal, MRI pituitary ordered. DEXA showed Z-score −1.6 at the lumbar spine. Dexamethasone suppression test negative."

Cushing’s Disease • Endocrine Disorders • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Muscular Atrophy • Musculoskeletal Pain

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. (PubMed, Sci Rep) - "BPC 157 appears to exert protective effects against skeletal muscle I/R injury by attenuating oxidative stress, modulating apoptosis, reducing inflammation, and supporting angiogenic activity. These findings suggest that BPC 157 may represent a potential therapeutic candidate for mitigating reperfusion injury; however, further studies with larger cohorts and dose-response evaluations are required to confirm these effects and establish clinical relevance."

IO biomarker • Journal • Preclinical • Cardiovascular • Inflammation • Peripheral Arterial Disease • Reperfusion Injury • BCL2 • CASP3 • HIF1A • IL6 • NOS3 • TP53 • VEGFA

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. (PubMed, Pharmaceutics) - "The primary barrier to clinical translation is not the absence of biological activity, but the absence of fundamental pharmaceutical science: characterized formulations, validated pharmacokinetics, and a coherent drug development strategy. Addressing these biopharmaceutical gaps is a prerequisite for any meaningful clinical program."

Journal • Review

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. (PubMed, Int J Mol Sci) - "Our results suggest that therapeutic peptides are a promising tool for treating type 2 diabetes and obesity, for skin rejuvenation, and as hormone analogs for specific diseases and conditions. Although these are strategic and innovative options that can improve health, performance, and longevity, further studies are needed before most new peptides can be used safely in humans."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Preventive care • Type 2 Diabetes Mellitus

Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. (PubMed, J Clin Med) - "Endothelial integrity primarily enhances maximal efficacy, while residual effects indicate additional mechanisms. These findings provide early mechanistic evidence for the vascular activity of BPC 157, although further molecular and in vivo studies are required to clarify its clinical relevance."

Journal

Synergistic Effects of Shewanella algae A3 and Serratia marcescens Van80 UB3 on Immune Response, Gene Expression and Resistance to Vibrio parahaemolyticus Vp5 in Pacific White Shrimp. (PubMed, J Fish Dis) - "A total of 150 shrimp of post larvae-10 (PL-10) were divided into five treatment groups: probiotic A (S...Histological observations revealed that the intestine and hepatopancreas tissues in probiotic-treated shrimp were in better and more normal condition compared to the positive control. Overall, the findings suggest that supplementing shrimp diets with a combination of S. algae A3 and S. marcescens Van80 UB3 at 106 cfu/g of feed is effective in improving shrimp health and resistance to AHPND."

Journal • Infectious Disease • CTSL

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. (PubMed, Front Aging) - "Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Therapeutic peptides offer mechanistically diverse approaches to multiple aging hallmarks. While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension."

Journal • Review • Metabolic Disorders

An Initial Evaluation of Body Protective Compound 157 (BPC-157) a peptide, as treatment for Musculoskeletal pain (ASRA-SPRING 2026) - "Together, these effects suggest BPC-157 may serve as a safe and effective non-opioid alternative for managing acute musculoskeletal pain. Larger controlled clinical trials are needed to validate these findings and establish standardized protocols for therapeutic use."

Addiction (Opioid and Alcohol) • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Substance Abuse • IL10 • IL1B • TNFA